Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Prognostic significance of matrix metalloproteinase-9 (MMP-9) in stage II colorectal carcinoma.

Buhmeida A, Bendardaf R, Hilska M, Collan Y, Laato M, Syrjänen S, Syrjänen K, Pyrhönen S.

J Gastrointest Cancer. 2009;40(3-4):91-7. doi: 10.1007/s12029-009-9091-x.

PMID:
19921474
2.

PLA2 (group IIA phospholipase A2) as a prognostic determinant in stage II colorectal carcinoma.

Buhmeida A, Bendardaf R, Hilska M, Laine J, Collan Y, Laato M, Syrjänen K, Pyrhönen S.

Ann Oncol. 2009 Jul;20(7):1230-5. doi: 10.1093/annonc/mdn783. Epub 2009 Mar 10.

PMID:
19276398
3.

MMP-9 (gelatinase B) expression is associated with disease-free survival and disease-specific survival in colorectal cancer patients.

Bendardaf R, Buhmeida A, Hilska M, Laato M, Syrjänen S, Syrjänen K, Collan Y, Pyrhönen S.

Cancer Invest. 2010 Jan;28(1):38-43. doi: 10.3109/07357900802672761.

PMID:
20001295
4.

Expression of cell cycle regulators p21 and p27 as predictors of disease outcome in colorectal carcinoma.

Al-Maghrabi J, Al-Ahwal M, Buhmeida A, Syrjänen K, Sibyani A, Emam E, Ghanim A, Al-Qahtani M.

J Gastrointest Cancer. 2012 Jun;43(2):279-87. doi: 10.1007/s12029-011-9292-y.

PMID:
21637966
5.

Loss of E-cadherin expression predicts disease recurrence and shorter survival in colorectal carcinoma.

Elzagheid A, Buhmeida A, Laato M, El-Faitori O, Syrjänen K, Collan Y, Pyrhönen S.

APMIS. 2012 Jul;120(7):539-48. doi: 10.1111/j.1600-0463.2011.02863.x. Epub 2012 Jan 23.

PMID:
22716209
6.

High expression of matrix metalloproteinases: MMP-2 and MMP-9 predicts poor survival outcome in colorectal carcinoma.

Salem N, Kamal I, Al-Maghrabi J, Abuzenadah A, Peer-Zada AA, Qari Y, Al-Ahwal M, Al-Qahtani M, Buhmeida A.

Future Oncol. 2016 Feb;12(3):323-31. doi: 10.2217/fon.15.325. Epub 2016 Jan 19.

PMID:
26814712
7.

Loss of MUC2 expression predicts disease recurrence and poor outcome in colorectal carcinoma.

Elzagheid A, Emaetig F, Buhmeida A, Laato M, El-Faitori O, Syrjänen K, Collan Y, Pyrhönen S.

Tumour Biol. 2013 Apr;34(2):621-8. doi: 10.1007/s13277-012-0588-8. Epub 2012 Nov 21.

PMID:
23179399
8.

Prognostic and diagnostic implications of MMP-2, MMP-9, and VEGF-α expressions in colorectal cancer.

Araújo RF Jr, Lira GA, Vilaça JA, Guedes HG, Leitão MC, Lucena HF, Ramos CC.

Pathol Res Pract. 2015 Jan;211(1):71-7. doi: 10.1016/j.prp.2014.09.007. Epub 2014 Oct 7.

PMID:
25446246
9.

DNA image cytometry predicts disease outcome in stage II colorectal carcinoma.

Buhmeida A, Hilska M, Elzagheid A, Laato M, Collan Y, Syrjänen K, Pyrhönen S.

Anticancer Res. 2009 Jan;29(1):99-106.

10.

CYP24A1 is a potential biomarker for the progression and prognosis of human colorectal cancer.

Sun H, Wang C, Hao M, Sun R, Wang Y, Liu T, Cong X, Liu Y.

Hum Pathol. 2016 Apr;50:101-8. doi: 10.1016/j.humpath.2015.11.008. Epub 2015 Nov 28.

PMID:
26997443
11.

Neutrophil gelatinase-associated lipocalin (NGAL) and matrix metalloproteinase-9 (MMP-9) prognostic value in stage I colorectal carcinoma.

Barresi V, Reggiani-Bonetti L, Di Gregorio C, Vitarelli E, Ponz De Leon M, Barresi G.

Pathol Res Pract. 2011 Aug 15;207(8):479-86. doi: 10.1016/j.prp.2011.05.012. Epub 2011 Jul 2.

PMID:
21726963
12.

Integrin αvβ6 and matrix metalloproteinase 9 correlate with survival in gastric cancer.

Lian PL, Liu Z, Yang GY, Zhao R, Zhang ZY, Chen YG, Zhuang ZN, Xu KS.

World J Gastroenterol. 2016 Apr 14;22(14):3852-9. doi: 10.3748/wjg.v22.i14.3852.

13.

Expression and prognostic value of matrix metalloproteinase-7 in colorectal cancer.

Yang B, Su K, Gao J, Rao Z.

Asian Pac J Cancer Prev. 2012;13(3):1049-52.

14.

Cyclooxygenase-2 expression as a predictor of outcome in colorectal carcinoma.

Al-Maghrabi J, Buhmeida A, Emam E, Syrjänen K, Sibiany A, Al-Qahtani M, Al-Ahwal M.

World J Gastroenterol. 2012 Apr 21;18(15):1793-9. doi: 10.3748/wjg.v18.i15.1793.

15.

High expression of COUP-TF II cooperated with negative Smad4 expression predicts poor prognosis in patients with colorectal cancer.

Wang C, Zhou Y, Ruan R, Zheng M, Han W, Liao L.

Int J Clin Exp Pathol. 2015 Jun 1;8(6):7112-21. eCollection 2015.

16.

Phosphorylated p38, a negative prognostic biomarker, complements TNM staging prognostication in colorectal cancer.

Fan XJ, Wan XB, Fu XH, Wu PH, Chen DK, Wang PN, Jiang L, Wang DH, Chen ZT, Huang Y, Wang JP, Wang L.

Tumour Biol. 2014 Oct;35(10):10487-95. doi: 10.1007/s13277-014-2320-3. Epub 2014 Jul 24.

PMID:
25056534
17.

Gelatinase B expression as a prognostic factor in patients with stage II/III rectal carcinoma treated by postoperative adjuvant therapy.

Unsal D, Akyurek N, Uner A, Erpolat OP, Han U, Akmansu M, Mentes BB, Dursun A.

Am J Clin Oncol. 2008 Feb;31(1):55-63. doi: 10.1097/COC.0b013e318068b4e2.

PMID:
18376229
18.

Clinicopathological significance and prognostic value of MMP-13 expression in colorectal cancer.

Yang B, Gao J, Rao Z, Shen Q.

Scand J Clin Lab Invest. 2012 Oct;72(6):501-5. doi: 10.3109/00365513.2012.699638. Epub 2012 Sep 5.

PMID:
22950625
19.

Expression of phospho-mTOR kinase is abundant in colorectal cancer and associated with left-sided tumor localization.

Melling N, Simon R, Izbicki JR, Terracciano LM, Bokemeyer C, Sauter G, Marx AH.

Int J Clin Exp Pathol. 2015 Jun 1;8(6):7009-15. eCollection 2015.

20.

Associations of beta-catenin alterations and MSI screening status with expression of key cell cycle regulating proteins and survival from colorectal cancer.

Wangefjord S, Brändstedt J, Lindquist KE, Nodin B, Jirström K, Eberhard J.

Diagn Pathol. 2013 Jan 21;8:10. doi: 10.1186/1746-1596-8-10.

Supplemental Content

Support Center